130
Views
1
CrossRef citations to date
0
Altmetric
Oncology

A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors

, , , , &
Pages 4485-4498 | Received 21 Jun 2023, Accepted 19 Sep 2023, Published online: 04 Oct 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
  • Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006;96:223–268. doi:10.1007/3-7643-7378-4_10
  • Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653–660. doi:10.1038/nm0603-653
  • Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333(26):1757–1763.
  • Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. PMID: 30231931; PMCID: PMC6146601. doi:10.1186/s13045-018-0664-7
  • Kerbel RS. A decade of experience in developing preclinical models of advanced- or early-stage spontaneous metastasis to study antiangiogenic drugs, metronomic chemotherapy, and the tumor microenvironment. Cancer J. 2015;21(4):274–283. PMID: 26222079. doi:10.1097/PPO.0000000000000134
  • Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):47. PMID: 31046803; PMCID: PMC6498593. doi:10.1186/s13045-019-0736-3
  • Desai J, Deva S, Lee JS, et al. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer. 2020;8(1):e000453. PMID: 32540858; PMCID: PMC7295442. doi:10.1136/jitc-2019-000453
  • Ghahremanloo A, Soltani A, Modaresi SMS, Hashemy SI. Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol. 2019;42(5):609–626. PMID: 31201647. doi:10.1007/s13402-019-00456-w
  • Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434–452. PMID: 29562194; PMCID: PMC7116507. doi:10.1016/j.immuni.2018.03.014
  • Fucà G, De Braud F, Di Nicola M. Immunotherapy-based combinations: an update. Curr Opin Oncol. 2018;30(5):345–351. PMID: 29994900. doi:10.1097/CCO.0000000000000466
  • Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. PMID: 30925919; PMCID: PMC6441150. doi:10.1186/s12943-019-0974-6
  • Chu T, Zhang W, Zhang B, et al. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Transl Lung Cancer Res. 2022;11(7):1394–1404. PMID: 35958322; PMCID: PMC9359953. doi:10.21037/tlcr-22-438
  • Su Y, Luo B, Lu Y, et al. Anlotinib Induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2022;28(4):793–809. PMID: 34844980; PMCID: PMC9377760. doi:10.1158/1078-0432.CCR-21-2241
  • Zheng W, Sun G, Li Z, et al. The effect of anlotinib combined with anti-PD-1 in the Treatment of gastric cancer. Front Surg. 2022;9:895982. PMID: 35495754; PMCID: PMC9039330. doi:10.3389/fsurg.2022.895982
  • Manegold C, Dingemans AC, Gray JE, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol Res. 2019;7(4):630–643. PMID: 30755403. doi:10.1158/2326-6066.CIR-17-0640
  • Wang Q, Gao J, Di W, Wu X. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. Cancer Immunol Immunother. 2020;69(9):1781–1799. PMID: 32347357. doi:10.1007/s00262-020-02576-x
  • Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679. PMID: 28404866; PMCID: PMC5554432. doi:10.1126/scitranslmed.aak9679
  • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
  • Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012;32(12):1095–1111. PMID: 23208836; PMCID: PMC3555403. doi:10.1002/phar.1147
  • Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654–661. PMID: 29438373; PMCID: PMC5846072. doi:10.1038/bjc.2017.478
  • Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. PMID: 30098152; PMCID: PMC6248083. doi:10.1001/jamaoncol.2018.3039
  • Shi J, Cheng Y, Wang Q, et al. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized Phase 2 study (ALTER1202). Front Med. 2022;16(5):766–772. PMID: 35844026. doi:10.1007/s11684-021-0916-8
  • Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171–6180. PMID: 20631075; PMCID: PMC2912959. doi:10.1158/0008-5472.CAN-10-0153
  • Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19(2):393–403. PMID: 23204132; PMCID: PMC4120472. doi:10.1158/1078-0432.CCR-12-1626
  • Georganaki M, Van Hooren L, Dimberg A. Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol. 2018;9:3081. PMID: 30627131; PMCID: PMC6309238. doi:10.3389/fimmu.2018.03081
  • Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J Clin Oncol. 2022;40(16):1795–1805. PMID: 35192397; PMCID: PMC9148684. doi:10.1200/JCO.21.02091
  • Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(17):1470–1478. PMID: 30943124. doi:10.1200/JCO.18.01265
  • Hao YY, Qiao YP, Cheng JD. Clinical activity and safety of anlotinib combined with PD-1 blockades for patients with previously treated small cell lung cancer. Int J Gen Med. 2021;14:10483–10493. PMID: 35002304; PMCID: PMC8722563. doi:10.2147/IJGM.S337316
  • Chen Q, Li Y, Zhang W, Wang C, Yang S, Guo Q. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study. J Cancer Res Clin Oncol. 2022;148(2):401–408. PMID: 34797416; PMCID: PMC8800903. doi:10.1007/s00432-021-03858-2
  • Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. Cancer Med. 2023;12(5):5372–5383. PMID: 36250532; PMCID: PMC10028028. doi:10.1002/cam4.5360
  • Yuan M, Zhu Z, Mao W, et al. Anlotinib combined with anti-PD-1 antibodies therapy in patients with advanced refractory solid tumors: a single-center, observational, prospective study. Front Oncol. 2021;7;11:683502. PMID: 34692475; PMCID: PMC8529018. doi:10.3389/fonc.2021.683502
  • Wallis CJD, Lawson K, Butaney M, et al. Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. Jpn J Clin Oncol. 2020;50(7):800–809. PMID: 32083295. doi:10.1093/jjco/hyaa021
  • Liu X, Guo CY, Tou FF, et al. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: a systematic review and meta-analysis. Int J Cancer. 2020;147(1):116–127. PMID: 31633798. doi:10.1002/ijc.32744